List of Excipients in Branded Drug FIORINAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	FIORINAL	butalbital, aspirin, and caffeine	0023-6146	CELLULOSE, MICROCRYSTALLINE
Allergan Inc	FIORINAL	butalbital, aspirin, and caffeine	0023-6146	D&C YELLOW NO. 10
Allergan Inc	FIORINAL	butalbital, aspirin, and caffeine	0023-6146	FD&C GREEN NO. 3
Allergan Inc	FIORINAL	butalbital, aspirin, and caffeine	0023-6146	FERRIC OXIDE RED

Fiorinal Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

FIORINAL contains butalbital 50 mg, aspirin 325 mg, and caffeine 40 mg per capsule. Its commercial opportunity is not based on new active-ingredient exclusivity. It lies in differentiated oral dosage forms, improved tolerability, supply-chain control, and compliant product positioning in a mature generic market. The principal constraints are butalbital dependence risk, aspirin-related gastrointestinal toxicity, controlled-substance regulation, and limited willingness to pay for an established combination product.

What is Fiorinal and how is it regulated?

FIORINAL is an oral capsule indicated for the relief of the symptom complex of tension headache. Each capsule contains:

Component	Strength per capsule	Function
Butalbital	50 mg	Barbiturate sedative
Aspirin	325 mg	Analgesic
Caffeine	40 mg	Analgesic adjuvant

The product is administered by prescription. Because it contains butalbital, FIORINAL is regulated as a Schedule III controlled substance in the United States. The labeling warns about habit formation, medication-overuse headache, central nervous system depression, and potentially fatal respiratory depression when combined with opioids, benzodiazepines, alcohol, or other sedatives (U.S. Food and Drug Administration [FDA], 2023).

FIORINAL is distinct from FIORINAL WITH CODEINE. The latter contains codeine and has a materially different controlled-substance, abuse-deterrence, labeling, and risk profile. Excipient and formulation strategies for FIORINAL should not be transferred automatically to the codeine product.

What excipients are used in Fiorinal capsules?

The marketed capsule formulation includes conventional excipients used for powder flow, capsule manufacture, color, and physical stability. FDA labeling identifies inactive ingredients including corn starch, FD&C Yellow No. 6, gelatin, lactose, magnesium stearate, povidone, talc, and titanium dioxide, although the precise supplier and grade may vary by manufacturer and approved product version (FDA, 2023).

Functional role of the principal excipients

Excipient	Likely formulation role	Commercial relevance
Lactose	Diluent and carrier	Low cost, but creates a lactose-free positioning issue
Corn starch	Diluent, disintegrant, processing aid	Supports capsule fill and release
Povidone	Binder and granulation aid	Controls powder cohesion and content uniformity
Magnesium stearate	Lubricant	Excess levels can slow dissolution
Talc	Glidant or anti-adherent	Supplier quality and elemental impurity controls matter
Gelatin	Hard-shell capsule material	Creates animal-origin and capsule-shell considerations
Titanium dioxide	Opacifier	Subject to jurisdiction-specific regulatory scrutiny
FD&C Yellow No. 6	Capsule colorant	Supports product identification but may limit clean-label positioning

The most commercially relevant excipient issues are lactose, gelatin, titanium dioxide, synthetic colorants, and the compatibility of the formulation with modified capsule shells.

What excipient strategy is most attractive for Fiorinal?

The strongest strategy is a controlled reformulation rather than a broad redesign. The formulation must preserve rapid and reproducible release of all three active ingredients while reducing avoidable excipient and manufacturing liabilities.

Lactose-free formulation

A lactose-free capsule could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a combination of microcrystalline cellulose and starch. The choice depends on powder density, flow, capsule fill weight, blend uniformity, dissolution, and chemical stability.

Mannitol may support a more differentiated patient profile because it is commonly associated with lactose-free and sugar-free formulations. It can, however, alter powder flow and tablet or capsule fill behavior. Microcrystalline cellulose is a conventional low-cost replacement but may increase bulk volume and affect blend uniformity at low active concentrations.

A lactose-free claim would be commercially useful only if supported by supplier controls, validated analytical testing, and clear labeling. It is unlikely to create strong patent protection by itself because the substitution is generally obvious and easy for competitors to replicate.

Colorant reduction or removal

A color-free or reduced-color capsule could appeal to patients and pharmacies seeking simpler excipient profiles. The commercial value is greater for private-label, specialty-pharmacy, and online prescribing channels than for the broad generic market.

Colorant removal creates practical challenges:

• Capsule identification may become less distinctive.
• Generic substitution appearance may change.
• Light protection must be reassessed.
• Packaging and imprinting may need to carry more of the identification burden.
• Dissolution and stability must be confirmed with the new shell and printing system.

A manufacturer could use an opaque, uncolored shell with a distinctive imprint rather than relying on FD&C Yellow No. 6.

Titanium-dioxide-free capsule shell

A titanium-dioxide-free capsule may improve international marketability and reduce regulatory friction in jurisdictions that restrict or scrutinize titanium dioxide in medicines. The United States has not established a general prohibition on titanium dioxide in approved oral drug products, but European regulatory policy has created pressure for manufacturers to evaluate alternatives.

Potential alternatives include calcium carbonate, starch-based opacifiers, iron oxides, and opaque natural-color systems. Each alternative can change capsule appearance, light transmission, moisture uptake, and dissolution. The opportunity is strongest for a global product platform rather than a United States-only generic.

Gelatin-free capsule shell

Hydroxypropyl methylcellulose capsules could support vegetarian, halal, kosher, and animal-origin-free positioning. The change requires evaluation of:

• Moisture transfer between shell and fill material
• Capsule brittleness
• Shell-machine compatibility
• Disintegration and dissolution
• Stability under warehouse conditions
• Interaction with hygroscopic excipients

A plant-based capsule may create a useful commercial distinction, but it will not by itself provide robust market exclusivity. The value depends on combining the shell change with lactose-free, color-free, or global-market positioning.

What formulations are protected by Fiorinal patents?

The core FIORINAL combination is an old, established drug product. The principal commercial products are not protected by a modern active-ingredient patent estate comparable to newer small-molecule drugs. Generic versions are widely available, and the product’s market position is driven primarily by regulatory approval, manufacturing capability, prescribing history, and controlled-substance distribution controls.

The relevant intellectual-property opportunities are likely to involve later-developed formulation claims, such as:

• Capsule-shell compositions
• Taste-masked or abuse-deterrent presentations
• Modified-release dosage forms
• Stabilized aspirin-containing blends
• Low-dust manufacturing processes
• Unit-dose packaging systems
• Specific excipient ratios tied to dissolution or stability
• Methods for reducing degradation or improving content uniformity

A formulation patent would need a technically meaningful limitation. A claim directed only to replacing lactose with mannitol or changing a capsule color would face substantial validity and obviousness risk. Stronger claims could arise from a demonstrated dissolution profile, unusual stability improvement, manufacturing problem, or controlled-release architecture that is difficult to reproduce.

When does Fiorinal lose exclusivity?

FIORINAL has no practical new-drug exclusivity barrier comparable to a recently approved product. The active ingredients and combination have been marketed for decades, and generic competition is established.

Exclusivity category	Commercial status
New chemical entity exclusivity	Expired or not relevant
Orphan-drug exclusivity	Not applicable to the established product
Pediatric exclusivity	No current commercial significance identified
Active-ingredient patent exclusivity	Not a meaningful barrier
Formulation exclusivity	Product-specific and potentially available only through later innovation
Regulatory approval barrier	ANDA approval remains necessary
Controlled-substance controls	Material operating barrier, but not market exclusivity

The commercial question is therefore not whether a generic can enter. Generic entry has already occurred. The question is whether a new entrant can secure supply, obtain approval, differentiate the product, and achieve favorable pharmacy and payer economics.

What is the Orange Book status of Fiorinal?

The FDA Orange Book lists approved prescription products and certain patent and exclusivity information. A legacy product such as FIORINAL should be assessed by its specific NDA, formulation, and current marketing status rather than by brand name alone. The relevant regulatory record is associated with the FIORINAL NDA and any approved supplements, while generic products are generally approved through ANDAs with therapeutic-equivalence designations where applicable (FDA, 2024a).

For a commercial diligence review, the key Orange Book questions are:

1. Whether the reference listed drug remains actively marketed.
2. Whether the relevant dosage form and strength remain eligible for ANDA referencing.
3. Whether any patent or exclusivity listings remain active.
4. Whether a generic applicant must address any listed patent through certification.
5. Whether the proposed product is therapeutically equivalent to the specific reference product.

Because FIORINAL is an old immediate-release combination capsule, the main regulatory risk is usually product-specific approval and manufacturing compliance, not a blocking patent.

Are Paragraph IV challenges relevant to Fiorinal?

Paragraph IV litigation is unlikely to be the central entry risk for a conventional FIORINAL generic. A Paragraph IV certification applies when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. For an old combination product with established generic competition, the greater risks are usually:

• Failure to demonstrate bioequivalence
• Inadequate stability data
• Content-uniformity problems
• Aspirin degradation
• Controlled-substance compliance failures
• Manufacturing inspection findings
• Supply interruptions
• Labeling differences
• Inability to source qualified excipients or capsule shells

A later reformulation could create a new patent dispute if a sponsor secures valid formulation or manufacturing claims. That dispute would concern the later innovation, not the basic FIORINAL combination.

How strong is the patent estate for Fiorinal?

The legacy patent estate is weak as a market barrier. A reformulation patent estate could be moderate if it is built around measurable technical performance and supported by multiple claim categories.

Patent-strength assessment

Claim area	Likely strength	Reason
Basic butalbital/aspirin/caffeine combination	Low	Long-established product
Lactose-free substitution alone	Low	Common formulation design choice
Gelatin-free capsule shell alone	Low to moderate	Commercially useful but often predictable
Titanium-dioxide-free system with stability benefit	Moderate	Stronger if tied to validated performance
Abuse-deterrent formulation	Moderate to high	Requires technical proof and regulatory alignment
Modified-release formulation	Moderate to high	Greater development burden and clinical risk
Specialized stability platform	Moderate	Depends on demonstrated unexpected results
Unit-dose packaging process	Low to moderate	May provide narrow process protection
Manufacturing process with superior content uniformity	Moderate	Stronger if difficult to reproduce

The best intellectual-property strategy would combine composition claims, dissolution or stability claims, capsule-shell claims, and manufacturing-process claims. Filing only a broad excipient substitution patent would provide limited protection.

What manufacturing and IP barriers exist?

The formulation is simple in concept but operationally sensitive. Butalbital is present at a relatively low dose compared with the total capsule fill, making blend uniformity important. Aspirin introduces moisture and degradation concerns. Caffeine can affect powder flow and blend behavior.

Key technical barriers

Content uniformity

Low-dose butalbital requires validated mixing and segregation controls. Particle-size matching, ordered mixing, granulation, or carrier selection may be needed to maintain uniformity across the capsule batch.

Aspirin stability

Aspirin can hydrolyze in the presence of moisture, producing salicylic acid and acetic acid. Excipient water activity, capsule-shell moisture, packaging permeability, and warehouse conditions must be controlled. Aluminum-aluminum blister packaging may provide stronger moisture protection than standard high-density polyethylene bottles, although packaging cost and patient convenience differ.

Dissolution

Magnesium stearate concentration, lubricant blending time, particle-size distribution, and capsule-shell composition can affect dissolution. A reformulation must demonstrate release performance for butalbital, aspirin, and caffeine rather than relying on a single composite test.

Controlled-substance security

Butalbital products require inventory controls, recordkeeping, diversion monitoring, and compliant distribution. A sponsor must also manage suspicious-order monitoring and state-level controlled-substance requirements. These obligations can deter smaller manufacturers even when the product has no meaningful patent barrier.

Which commercial opportunities exist for a new Fiorinal product?

The most credible opportunities are niche and operational.

Opportunity 1: Lactose-free and excipient-reduced capsule

A lactose-free, titanium-dioxide-free, low-color capsule could target patients and prescribers seeking reduced excipient exposure. The positioning should remain medically conservative because the active ingredients drive most safety concerns.

Opportunity 2: Premium unit-dose packaging

Calendarized or unit-dose blister packaging could reduce dispensing errors, improve portability, and support controlled-substance accountability. Packaging will not eliminate abuse risk, but it may improve pharmacy handling and adherence for short treatment courses.

Opportunity 3: Global-ready formulation

A formulation designed from the outset without titanium dioxide, animal gelatin, and restricted colorants could reduce country-specific reformulation requirements. The addressable market would depend on national approvals because regulatory pathways for combination products differ across jurisdictions.

Opportunity 4: Abuse-deterrent development

An abuse-deterrent FIORINAL product could address manipulation or rapid-release concerns, but development costs and regulatory expectations would be high. Abuse-deterrence labeling would require evidence under FDA guidance and would not remove the risks associated with butalbital dependence or combination use with other sedatives (FDA, 2015).

Opportunity 5: Contract manufacturing and private label

The most immediate commercial opportunity may be supply rather than innovation. A reliable manufacturer with DEA-compliant operations, validated aspirin stability, and consistent capsule-fill performance could win business from distributors, hospital systems, and private-label sponsors.

Opportunity 6: Reformulation platform licensing

A sponsor could license a capsule-shell, moisture-control, or content-uniformity platform to multiple generic manufacturers. The value would depend on enforceable patents, regulatory transferability, and demonstrated reduction in deviations or batch failures.

How does Fiorinal compare with Fiorinal with Codeine?

Attribute	FIORINAL	FIORINAL WITH CODEINE
Active ingredients	Butalbital, aspirin, caffeine	Butalbital, aspirin, caffeine, codeine
Controlled-substance burden	Schedule III	Higher opioid-related compliance burden
Abuse and respiratory-depression risk	Material	Greater
Excipient strategy	Focus on stability, tolerability, capsule shell	Same issues plus opioid-risk positioning
Generic competition	Established	Established but more operationally complex
Commercial differentiation	Limited	Potentially greater, but regulatory risk is higher
Packaging opportunity	Unit-dose and diversion controls	Stronger need for controlled distribution and risk controls

A sponsor pursuing FIORINAL WITH CODEINE should treat it as a separate development and compliance program. The addition of codeine changes pharmacology, labeling, abuse risk, and market access considerations.

What generic launch scenarios exist for Fiorinal?

Conventional low-cost generic

This is the most likely and lowest-risk scenario. The sponsor uses a standard hard gelatin capsule, conventional excipients, and bottle packaging. Margin depends on manufacturing scale, supply reliability, and distributor access.

Differentiated excipient generic

A sponsor introduces lactose-free, color-free, gelatin-free, or titanium-dioxide-free positioning. The product may obtain modest price differentiation but remains vulnerable to rapid copying.

Premium packaging product

The product uses unit-dose blisters or calendar packaging. This may appeal to institutional pharmacies and controlled-substance dispensing channels, although packaging cost can reduce margin.

Reformulated product with patent protection

A sponsor develops modified release, abuse deterrence, or a technically novel stability platform. This scenario offers the greatest potential differentiation but carries the highest development, clinical, regulatory, and litigation risk.

What is the revenue exposure and competitive outlook?

FIORINAL is a mature, fragmented prescription market. Revenue is exposed to:

• Generic price compression
• Reduced use of butalbital-containing products
• Clinical preference for non-barbiturate headache treatment
• Medication-overuse headache concerns
• Controlled-substance prescribing restrictions
• Pharmacy purchasing consolidation
• Product discontinuations and shortages
• Competitive alternatives such as nonprescription analgesics, triptans, gepants, and other migraine therapies

A commercial model should not rely on brand-level revenue alone. It should separate:

1. Reference-brand sales
2. Authorized generic sales
3. Standard ANDA generic sales
4. Contract-manufacturing revenue
5. Reformulated or premium-packaging revenue

The strongest near-term thesis is stable supply and niche differentiation, not rapid market expansion.

Key Takeaways

• FIORINAL contains butalbital, aspirin, and caffeine in a 50/325/40 mg capsule.
• Its core combination has no meaningful modern patent barrier, and generic competition is established.
• The most practical excipient opportunities are lactose-free, titanium-dioxide-free, gelatin-free, color-reduced, and moisture-controlled formulations.
• Aspirin stability, low-dose butalbital content uniformity, dissolution, and controlled-substance compliance are the central technical barriers.
• A simple excipient substitution is unlikely to support a strong patent estate.
• Stronger IP could arise from abuse deterrence, modified release, measurable stability improvements, or manufacturing processes that solve reproducible technical problems.
• Unit-dose packaging and reliable controlled-substance manufacturing may create more immediate commercial value than a new excipient composition.
• FIORINAL WITH CODEINE is a separate and higher-risk product opportunity because codeine increases opioid-related regulatory and safety burdens.

FAQs

Is Fiorinal a good candidate for a lactose-free reformulation?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, starch, or another suitable diluent. The formulation must be revalidated for blend uniformity, dissolution, stability, and capsule-fill performance.

Can a company patent a new Fiorinal excipient combination?

Potentially, but a patent based only on routine excipient substitution would be vulnerable to obviousness challenges. Stronger protection requires unexpected stability, dissolution, manufacturing, or abuse-deterrence benefits.

Would a titanium-dioxide-free Fiorinal capsule have international value?

Yes. A global-ready capsule shell can reduce the need for jurisdiction-specific excipient changes. Its value is strongest when combined with gelatin-free and color-reduced positioning.

What is the main manufacturing risk for Fiorinal?

The main risks are aspirin degradation from moisture, low-dose butalbital content-uniformity failures, and dissolution changes caused by lubricant, particle-size, or capsule-shell modifications.

Can unit-dose packaging create a defensible Fiorinal business?

It can create a commercial niche, especially for institutional and specialty-pharmacy channels. Packaging alone is unlikely to create durable exclusivity unless supported by a proprietary system, measurable compliance benefit, or enforceable process claims.

References

1. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov
2. U.S. Food and Drug Administration. (2023). Fiorinal prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
4. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov
5. U.S. Drug Enforcement Administration. (2024). Controlled substance schedules. https://www.dea.gov